Royzen Lab has recently been in the news that highlight our collaboration with a San Francisco start-up Shasqi, Inc. Our collaboration resulted in a development of a Click Activated Protodrugs Against Cancer (CAPAC) platform, which is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors.
The Royzen research group was awarded an R21 grant from the National Human Genome Research Institute (NHGRI). The title of the grant is: Chemical synthesis and non-chromatographic purification of long RNA oligonucleotides containing naturally occurring modifications. Our collaborators, Dr. Jia Sheng and Dr. Gaby Fuchs are co-investigators on this award.
We welcome a new graduate student, Ian McClain, who just joined the Royzen research group with a background in biochemistry. He’ll be working on the development of new methods of solid phase synthesis of long RNA oligonucleotides, containing modifications. Ian received Albany RNA Institute’s fellowship for the 2022-2021 academic year.
Royzen Lab has recently been in the news that highlight our collaboration with a San Francisco start-up Shasqi, Inc. Our collaboration resulted in a development of a Click Activated Protodrugs Against Cancer (CAPAC) platform, which is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors.
Congratulations to Muhan He who successfully defended her PhD dissertation, titled: Development of chemical methods for oligonucleotide purification, paramagnetic labeling and synthesis of DNA-based advanced materials. Muhan’s most recent work, describing non-chromatographic purification of synthetic RNA has been uploaded to bioRxiv.
Our collaborative work with Shasqi, Inc. resulted in two publications which have been uploaded to bioRxiv and ChemRxiv. These manuscripts are currently undergoing peer review. These papers were recently discussed in a Science Translational Medicine Blog.
Our collaborative work with Lei Zhu Lab (FSU) was just accepted for publication in Bioconjugate Chemistry. Our publication describes in-cell labeling of proteins of interest using two orthogonal bio-orthogonal chemistries. Congratulations to everyone who contributed to this work.
Our collaborative work with Yigit Lab was just accepted for publication in ChemMedChem. The paper describes spectroscopic analysis of in-cell activation of doxorubicin. This work is supported by our collaborative R15 grant from NIGMS.
Our long awaited book chapter, titled: “In vivo bioconjugation using bio-orthogonal chemistry” has been published by Wiley. We would like to thank all the contributors.
Max Royzen has been promoted to Associate Professor! Thank you to all the colleagues, administrators, and group members past and present, who contributed to Prof. Royzen’s promotion.
After numerous updates and revisions, we finally published a Chem Comm paper describing imaging of ribosomal RNA in live mammalian cells. This work was started by Papa Nii six years ago, continued by Irfan and finished by Muhan And Kui. Congratulations to all the co-authors!
We welcome a new graduate student, Amir Agharezaee, who just joined the Royzen research group with a background in biochemistry. He’ll be working on RNA imaging in live cells.
Our collaborative work with Shasqi, Inc., as well as collaborators from Berlin has just been accepted for publication by ACS Central Science. Congratulations to Eddie, Chris, Hasina, Ilenis and Dr. Khan!
We received another collaborative SBIR grant with Shasqi, Inc. We would like to thank the NIGMS institute of the NIH for their generous support. This will be a 3-year grant focused on the development of bio-orthogonal chemistry-based drug delivery strategies.
We welcome the new postdoctoral scientist, Xunshen Wu, who just joined the Royzen research group from China. Dr. Wu completed his doctoral work past summer at the East China University of Science and Technology.